NORTH CHICAGO, Ill., Feb. 24, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved HUMIRA ® (adalimumab) for the treatment of moderately ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO – The VARSITY study results showed that clinical and endoscopic outcomes of Entyvio treatment were ...

HUMIRA (adalimumab) 40mg/0.8mL solution for SC inj by AbbVie Abbott announced that the FDA has approved Humira (adalimumab) for inducing and sustaining clinical remission in adult patients with ...

Please provide your email address to receive an email when new articles are posted on . Among the top stories in gastroenterology last week were trial results that maintained that Entyvio conferred ...

MONTREAL, April 22, 2021 /CNW/ - AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that Health Canada has approved HUMIRA ® (adalimumab) for inducing and ...

(RTTNews) - Biopharmaceutical company AbbVie (ABBV) Thursday said Health Canada has approved Humira (adalimumab) for inducing and maintaining clinical remission in pediatric patients five years of age ...

The pediatric approval was based on data from the multicenter, randomized, double-blind phase 3 ENVISION I study. The Food and Drug Administration (FDA) has expanded the approval of Humira ® ...

Thanks to the safety scrutiny on the JAK inhibitor class of drugs, AbbVie’s optimism for its Humira follow-on Rinvoq might have shifted from unbridled to cautious. But in the meantime, the versatile ...

FDA has announced it has expanded the approved use of Humira (adalimumab), manufactured by Abbott Laboratories, to include treatment of moderate-to-severe ulcerative colitis in adults, according to a ...

AbbVie’s blockbuster drug Humira has more competition coming—the first FDA-approved biosimilar that may be substituted for the monoclonal antibody at the pharmacy. The competing Boehringer Ingelheim ...